Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the first patient enrolled at Yale School of Medicine [1][2] - The trial will assess the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy in reducing alcohol cravings and consumption [2] - The U.S. substance use disorder treatment market was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, highlighting significant market potential for effective AUD treatments [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Clinical Trial Details - Eligible participants for the trial include individuals aged 18 to 60, either heavy binge drinkers or those diagnosed with AUD, who express a desire to reduce or stop drinking [3] - The trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, with additional sites under evaluation [3]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a proprietary treatment targeting anorexia, bulimia, and other eating disorders, highlighting its commitment to developing innovative therapies for under-treated mental health conditions [1][4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant health issues, including eating disorders and alcohol use disorder [5]. - The company currently holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [6]. Treatment Development - The new patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA), targeting the neurobiological and psychological factors associated with eating disorders [2]. - The company aims to provide new treatment options for individuals struggling with eating disorders through the therapeutic potential of 3-MMC and PEA [4]. Industry Context - Eating disorders are serious mental health conditions that significantly impact health, emotions, and daily functioning, with up to 70 million people affected globally [3]. - The prevalence of eating disorders increased from 3.4% to 7.8% between 2000 and 2018, indicating a growing public health concern [3].

Core Viewpoint - Clearmind Medicine Inc. has initiated its U.S. clinical trial for its psychedelic-derived treatment CMND-100 aimed at addressing Alcohol Use Disorder (AUD), marking a significant step in the development of innovative therapies for this under-treated health issue [1][3]. Group 1: Clinical Trial Details - The clinical trial site at Yale School of Medicine's Department of Psychiatry has been activated, with patient enrollment set to begin [1]. - The trial will be led by Dr. Anahita Bassir Nia, M.D., and will also take place at Johns Hopkins University School of Medicine and the IMCA Center in Israel [2]. Group 2: Company Overview and Objectives - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health problems, including AUD [4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discus ...

Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to its MEAI treatment for binge behavior. This new US patent provides additional intellectual property prot ...

Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly Alcohol Use Disorder (AUD) [1][7] - The company has a proprietary drug candidate, CMND-100, which is based on MEAI and aims to provide a novel treatment approach for AUD by modulating reward mechanisms associated with addictive behavior [4] Clinical Trial Initiation - Clearmind has initiated its Phase I/IIa clinical trial for CMND-100 at Johns Hopkins University School of Medicine, marking a significant milestone towards FDA approval [1][3] - The trial will also take place at Yale School of Medicine and IMCA Center in Israel, indicating a strong foundation for evaluating the clinical potential of CMND-100 [2][3] Study Objectives - The clinical trial is designed to assess the safety, tolerability, and pharmacokinetics of CMND-100 in individuals diagnosed with AUD, along with preliminary efficacy evaluations to examine its potential in reducing alcohol cravings and consumption [3] Market Context - Alcohol Use Disorder is a major global health challenge, affecting approximately 400 million people aged 15 and older, with 209 million experiencing alcohol dependence [6] - The disorder contributes to 2.6 million deaths annually, accounting for 4.7% of all global deaths, highlighting the urgent need for innovative therapeutic solutions [6] Regulatory and Intellectual Property - Clearmind aims to commercialize its psychedelic-based compounds as regulated medicines, foods, or supplements, and currently holds a portfolio of nineteen patent families with 31 granted patents [7][8]

Core Insights - Clearmind Medicine Inc. has announced the publication of an international patent application in collaboration with Yissum Research Development Company, focusing on innovative psychedelic-based compounds for treating mental health disorders and addiction [1][2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to discovering and developing novel psychedelic-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [3] - The company currently holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [4] Collaboration and Innovation - The collaboration with Yissum has produced highly innovative compounds that aim to surpass the limitations of traditional psychedelics, reflecting the company's commitment to advancing safe and effective solutions for mental health and addiction disorders [2] - The patent application is part of an exclusive worldwide licensing agreement with Yissum, allowing Clearmind to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds [2]

Core Insights - Clearmind Medicine Inc. has launched its Electronic Data Capture (EDC) system to support its Phase I/II clinical trial for a MEAI-based treatment targeting Alcohol Use Disorder (AUD) [1][2][5] - The EDC system is designed for real-time, secure data collection and monitoring across all trial sites, ensuring compliance and integrity of the study [2][3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly alcohol use disorder [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [7] Clinical Trial Details - The clinical trial aims to evaluate the safety, tolerability, and efficacy of Clearmind's MEAI-based compound in individuals with AUD [1][2] - The EDC system includes features such as automated edit checks, real-time validation, and a secure randomization process to enhance data accuracy and compliance [3][4]

Core Insights - Clearmind Medicine Inc. has announced the arrival of its drug candidate CMND-100 in the U.S., marking a significant milestone as it prepares to initiate its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) [1][2][3] - CMND-100 is a proprietary MEAI-based oral drug that aims to reduce alcohol consumption and cravings through a novel mechanism of action, positioning the company to potentially disrupt the AUD treatment market [2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company has a robust intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [5] Market Opportunity - The global market opportunity for AUD treatments is estimated at $35 billion, with current solutions being limited and ineffective [3] - The Phase I/IIa clinical trial will assess the safety and efficacy of CMND-100 in reducing alcohol consumption, conducted at leading research institutions including Yale and Johns Hopkins [3]

Core Insights - Clearmind Medicine Inc. has announced the arrival of its drug candidate CMND-100 in the U.S., marking a significant milestone as it prepares to initiate its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) [1][2][3] - CMND-100 is a proprietary MEAI-based oral drug that aims to reduce alcohol consumption and cravings through a novel mechanism of action, positioning Clearmind to potentially disrupt the AUD treatment market [2][3] - The global market opportunity for AUD treatments is estimated at $35 billion, with Clearmind's innovative approach addressing a significant unmet need in this space [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [5] Clinical Trial Details - The Phase I/IIa clinical trial will evaluate the safety and efficacy of CMND-100 in reducing alcohol consumption and will be conducted at Yale School of Medicine and Johns Hopkins University School of Medicine in the U.S., as well as at IMCA in Israel [3]